Drug Enforcement Administration June 28, 2021 – Federal Register Recent Federal Regulation Documents

Importer of Controlled Substances Application: AMRI Rensselaer, Inc.
Document Number: 2021-13672
Type: Notice
Date: 2021-06-28
Agency: Drug Enforcement Administration, Department of Justice
AMRI Rensselaer, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Bulk Manufacturer of Controlled Substances Application: Chemic Laboratories
Document Number: 2021-13671
Type: Notice
Date: 2021-06-28
Agency: Drug Enforcement Administration, Department of Justice
Chemic Laboratories, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
Registration Requirements for Narcotic Treatment Programs With Mobile Components
Document Number: 2021-13519
Type: Rule
Date: 2021-06-28
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) is publishing this final rule to revise existing regulations for narcotic treatment programs (NTPs) to allow the operation of a mobile component associated with a DEA-registered NTP to be considered a coincident activity permitted under the NTP's registration. Based on these revisions, NTP registrants that operate or wish to operate mobile components (in the State in which the registrant is registered) to dispense narcotic drugs in schedules II-V at remote location(s) for the purpose of maintenance or detoxification treatment do not need a separate registration for such mobile component. This final rule waives the requirement of a separate registration at each principal place of business or professional practice where controlled substances are dispensed for those NTPs with mobile components that fully comply with the requirements of this rule. These revisions to the regulations are intended to make maintenance or detoxification treatments more widely available, while ensuring that safeguards are in place to reduce the likelihood of diversion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.